The financials
Moderna by the numbers
Moderna (MRNA) reported revenue of $145M in Q2 2026 (quarter ended June 30, 2026), up 2.1% from the same quarter a year earlier. That came with a gross margin of 36% and net loss of $782M. For the full year FY2025, revenue was $1.94B (−40% year on year) and net income −$2.82B. Its largest product in 2026-Q1 was COVID19 at $345M, 81% of the disclosed total, just ahead of Product And Service Other at 8.7%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $145M | $142M | +2.1% |
| Gross profit | $52M | $23M | +126% |
| Operating income | −$815M | −$907M | n/a |
| Net income | −$782M | −$825M | n/a |
| Diluted EPS | −$1.97 | −$2.13 | n/a |
| Product | Revenue | Share |
|---|---|---|
| COVID19 | $345M | 81% |
| Product And Service Other | $37M | 8.7% |
| Stand Ready Manufacturing | $32M | 7.5% |
| RSV | $7.0M | 1.6% |
| Collaboration Arrangement Including Arrangements With Affiliate | $5.0M | 1.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $426.0M (-60%)
Collaboration Arrangement Including Arrangements With Affiliate grew +400% year on yearLicense And Royalty -100% year on year
Segment Latestquarter on quarteryear on year
- COVID19$345.0M$345.0MQoQ -64%year on year +311%-64%+311%
- Product And Service Other$37.0M$37.0MQoQ -14%year on year +68%-14%+68%
- Stand Ready Manufacturing$32.0M$32.0MQoQ -year on year +167%-+167%
- RSV$7.0M$7.0MQoQ +250%year on year +250%+250%+250%
- Collaboration Arrangement Including Arrangements With Affiliate$5.0M$5.0MQoQ -29%year on year +400%-29%+400%
- Grant$0.00$0.00QoQ -100%year on year -100%-100%-100%
- License And Royalty$0.00$0.00QoQ -100%year on year -100%-100%-100%
- Other--QoQ -year on year ---
Biotechnology
Ranks #30 of 145 by Smart Score